Dimensional Fund Advisors LP Raises Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Dimensional Fund Advisors LP increased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 7.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,137,201 shares of the biotechnology company’s stock after purchasing an additional 349,837 shares during the period. Dimensional Fund Advisors LP owned approximately 1.69% of Exelixis worth $115,434,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Resonant Capital Advisors LLC increased its holdings in Exelixis by 3.6% in the second quarter. Resonant Capital Advisors LLC now owns 13,746 shares of the biotechnology company’s stock valued at $309,000 after buying an additional 477 shares in the last quarter. Cornercap Investment Counsel Inc. increased its holdings in Exelixis by 1.1% in the second quarter. Cornercap Investment Counsel Inc. now owns 50,497 shares of the biotechnology company’s stock valued at $1,135,000 after buying an additional 539 shares in the last quarter. Alaska Permanent Fund Corp increased its holdings in Exelixis by 1.2% in the first quarter. Alaska Permanent Fund Corp now owns 53,239 shares of the biotechnology company’s stock valued at $1,263,000 after buying an additional 617 shares in the last quarter. Fisher Asset Management LLC grew its position in shares of Exelixis by 232.6% in the fourth quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 728 shares during the period. Finally, Banque Cantonale Vaudoise grew its position in shares of Exelixis by 11.5% in the first quarter. Banque Cantonale Vaudoise now owns 7,555 shares of the biotechnology company’s stock valued at $179,000 after purchasing an additional 781 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Activity

In other news, Director Maria C. Freire sold 8,250 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $26.56, for a total value of $219,120.00. Following the sale, the director now directly owns 91,007 shares of the company’s stock, valued at approximately $2,417,145.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Maria C. Freire sold 8,250 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $26.56, for a total value of $219,120.00. Following the sale, the director now directly owns 91,007 shares of the company’s stock, valued at approximately $2,417,145.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jeffrey Hessekiel sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $25.79, for a total transaction of $515,800.00. Following the completion of the sale, the executive vice president now directly owns 630,325 shares in the company, valued at $16,256,081.75. The disclosure for this sale can be found here. In the last three months, insiders have sold 302,858 shares of company stock valued at $7,980,629. Company insiders own 2.85% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on EXEL shares. UBS Group started coverage on shares of Exelixis in a research report on Thursday, September 19th. They issued a “neutral” rating and a $30.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $29.00 target price on shares of Exelixis in a research report on Wednesday, September 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $27.00 target price on shares of Exelixis in a research report on Wednesday, August 7th. JMP Securities reiterated a “market outperform” rating and issued a $29.00 target price on shares of Exelixis in a research report on Friday. Finally, Oppenheimer reiterated an “outperform” rating and issued a $29.00 target price on shares of Exelixis in a research report on Tuesday, July 30th. Five equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

Exelixis Price Performance

NASDAQ:EXEL opened at $26.36 on Tuesday. The firm has a market capitalization of $7.99 billion, a price-to-earnings ratio of 41.19, a PEG ratio of 0.58 and a beta of 0.54. The company’s 50-day moving average is $25.28 and its two-hundred day moving average is $23.38. Exelixis, Inc. has a 1-year low of $18.64 and a 1-year high of $27.83.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.44. The company had revenue of $637.18 million for the quarter, compared to analyst estimates of $468.21 million. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. As a group, equities analysts anticipate that Exelixis, Inc. will post 1.54 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.